ASCO 2021 | The highlight moment!

It is highly anticipated and ready to go.

As the pioneer and leader of China's innovative drug research and development, Hengrui Pharmaceuticals will bring a number of research and development drugs to the ASCO annual meeting this year.

"Shuangai Combination" was praised by CCTV as the "new nemesis" of liver cancer

"Shuangai Combination" was praised by CCTV as the "new nemesis" of liver cancer

In April this year, CCTV 2 sets of "Economy Half an Hour" column praised Hengrui Medicine Carrelizumab ( ^Erica®️ ) and Hengrui independently developed another innovative drug apatinib ( ^Aitan®️ ) The "Double Ai" program of China is called the "new nemesis" of persistent liver cancer diseases.

^{®️ ®️}

The "Double Ai" program has made breakthrough progress in the treatment of advanced liver cancer in recent years.

From a mechanism point of view, apatinib is a VEGFR-2 inhibitor, and the combination with carrelizumab, the PD-1 monoclonal antibody, can fundamentally change the immune microenvironment, thereby strengthening the PD-1 monoclonal antibody The effect of "1+1>2".

The combination of immunotherapy and anti-angiogenesis targeted drugs has gradually become the standard treatment for advanced liver cancer.

Hepatobiliary tumors: progress in multi-line treatment and more in-depth exploration

Hepatobiliary tumors: progress in multi-line treatment and more in-depth exploration

At this ASCO annual meeting, "Shuang Ai Combination" has a total of 5 studies in the field of liver cancer for data announcement and result update.

^{1 2 3}

In terms of perioperative treatment, a prospective, phase II study evaluating the efficacy and safety of carrelizumab combined with apatinib in the perioperative treatment of hepatocellular carcinoma was selected for the poster presentation of this conference.

^{4 5}

In terms of efficacy biomarkers, a study explored the efficacy biomarkers of carrelizumab combined with apatinib for neoadjuvant treatment of locally advanced cholangiocarcinoma.

⁶

In terms of other digestive system tumors, a phase Ib study of carrelizumab combined with apatinib neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma led by the Chinese Academy of Medical Sciences was included in the poster link.

^{7 8}

Lung cancer: combination therapy, exploration of more advanced patients

Lung cancer: combination therapy, exploration of more advanced patients

In the field of lung cancer, a total of 1 poster and 2 online abstracts were selected for this ASCO conference.

^{9 10 11}

Multi-tumor species, all blooming

Multi-tumor species, all blooming

In other tumor treatment fields, Professor Zhong Laiping from the Ninth People’s Hospital Affiliated to Shanghai Jiaotong University School of Medicine conducted a study of carrelizumab combined with apatinib in the induction treatment of resectable locally advanced oral squamous cell carcinoma.

^{12 13}

In addition, in terms of new drug combination therapy, the team of Professor Cheng Ying from Jilin Cancer Hospital has carried out a phase I study of IDO inhibitor (SHR9146) plus carrelizumab with or without apatinib in the treatment of advanced solid tumors.

¹⁴

In addition to the above-mentioned "Shuang Ai" related treatment research progress, Hengrui Medicine has been selected for this ASCO meeting with a total of more than 60 studies, involving the field of multi-tumor treatment, with fruitful results.

The above research results are from the official website of the 2021ASCO annual meeting, as of May 26, 2021.

references:

references:

1.

1.
Yun Zhang, Jianming Xu, Jie Shen, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 4076).

2.
Gang Liu, Liansheng Gong, Wenxuan Zhou, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16120)

2.
Gang Liu, Liansheng Gong, Wenxuan Zhou, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16120)

3.
Wenge Xing, Zhi Guo.
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4160)

3.
Wenge Xing, Zhi Guo.
J Clin Oncol 39, 2021 (suppl 15; abstr TPS4160)

4.
Yongxiang Xia, Ping Wang, Liyong Pu, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 4082)

4.
Yongxiang Xia, Ping Wang, Liyong Pu, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 4082)

5.
Zhiming Zeng, Guangzhi Zhu, Huasheng Huang, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16132)

5.
Zhiming Zeng, Guangzhi Zhu, Huasheng Huang, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16132)

6.
Zhen Wang.
J Clin Oncol 39, 2021 (suppl 15; abstr 4047)

6.
Zhen Wang.
J Clin Oncol 39, 2021 (suppl 15; abstr 4047)

7.
Song Li, Wenbin Yu, Fei Xie, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 4061).

7.
Song Li, Wenbin Yu, Fei Xie, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 4061).

8.
Jian-hua Rao, Chen Wu, Hui Zhang,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16126)

8.
Jian-hua Rao, Chen Wu, Hui Zhang,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e16126)

9.
Mingfang Zhao, Tao Han.
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9130)

9.
Mingfang Zhao, Tao Han.
J Clin Oncol 39, 2021 (suppl 15; abstr TPS9130)

10.
Rui Meng, Lu Wu, Kai Zhang,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e21128)

10.
Rui Meng, Lu Wu, Kai Zhang,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e21128)

11.
Yueyin Pan, Fengshou Jiang, Yingying Du,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e21051)

11.
Yueyin Pan, Fengshou Jiang, Yingying Du,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr e21051)

12.
Lai-Ping Zhong, Wu-tong Ju, Rong-hui Xia,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 6052)

12.
Lai-Ping Zhong, Wu-tong Ju, Rong-hui Xia,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 6052)

13.
Xuan Wang, Chuanliang Cui, Bin Lian,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 9539)

13.
Xuan Wang, Chuanliang Cui, Bin Lian,et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 9539)

14.
Ying Cheng, Ying Liu, Jinhua Xu, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 3101)

14.
Ying Cheng, Ying Liu, Jinhua Xu, et al.
J Clin Oncol 39, 2021 (suppl 15; abstr 3101)